Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase I clinical trial of dextromethorphan in intractable partial epilepsy
Autore:
Kimiskidis, VK; Mirtsou-Fidani, V; Papaioannidou, PG; Niopas, I; Georgiadis, G; Constadinidis, TC; Kazis, AD;
Indirizzi:
Aristotelian Univ Salonika, Sch Med, Dept Pharmacol, GR-54006 Salonika, Greece Aristotelian Univ Salonika Salonika Greece GR-54006 006 Salonika, Greece Aristotelian Univ Salonika, Dept Neurol 3, GR-54006 Salonika, Greece Aristotelian Univ Salonika Salonika Greece GR-54006 006 Salonika, Greece Aristotelian Univ Salonika, Dept Pharm, GR-54006 Salonika, Greece Aristotelian Univ Salonika Salonika Greece GR-54006 006 Salonika, Greece Aristotelian Univ Salonika, Biostat Unit, Hyg Lab, GR-54006 Salonika, Greece Aristotelian Univ Salonika Salonika Greece GR-54006 006 Salonika, Greece
Titolo Testata:
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
fascicolo: 10, volume: 21, anno: 1999,
pagine: 673 - 678
SICI:
0379-0355(199912)21:10<673:APICTO>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
NONKETOTIC HYPERGLYCINEMIA; NMDA RECEPTOR; DEXTRORPHAN; ANTAGONIST; ISCHEMIA; THERAPY; SAFETY;
Keywords:
dextromethorphan; dextrorphan; epilepsy; clinical trial; NMDA receptors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Mirtsou-Fidani, V Aristotelian Univ Salonika, Sch Med, Dept Pharmacol, GR-54006 Salonika, Greece Aristotelian Univ Salonika Salonika Greece GR-54006 ce
Citazione:
V.K. Kimiskidis et al., "A phase I clinical trial of dextromethorphan in intractable partial epilepsy", METH FIND E, 21(10), 1999, pp. 673-678

Abstract

We conducted an open-label pilot study of dextromethorphan (DM) in intractable partial epilepsy with the following objectives: a preliminary evaluation of the drug's safety and efficacy in the epileptic patient and a definition of a concentration range which can be safely achieved in future studies. Sixteen patients with drug-resistant, localization-related epilepsies entered the trial. After an 8-week baseline period, DM was added to the existing antiepileptic drugs at a dose of 40 and 50 mg every 6 h (160 and 200 mg/day). Each treatment period lasted 8 weeks. Seizure control improved after administration of DM, especially in the group of intermediate and slow metabolizers. Two patients, however, experienced increased seizure frequency and withdrew from rile study. Adverse effects during DM administration were mild and transient. DM,was well tolerated even in patients with high plasma levels of the drug (up to 15020 ng/dl). Our results indicate that DM is safe and effective bl the treatment of comedicated patients with intractable partial epilepsies. (C) 1999 Pious Science. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 08:13:26